These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 14594440)

  • 1. Pharmaceutical expenditure and therapeutic value of new medicines in Spain.
    Darba J
    Pharmacoeconomics; 2003; 21(16):1211-2. PubMed ID: 14594440
    [No Abstract]   [Full Text] [Related]  

  • 2. Pharmaceutical expenditure in Spain: cost and control.
    Lopez Bastida J; Mossialos E
    Int J Health Serv; 2000; 30(3):597-616. PubMed ID: 11109184
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmaceutical costs. An overview and analysis of legal and policy responses by the states.
    Latham SR
    J Leg Med; 2003 Jun; 24(2):141-73. PubMed ID: 12775406
    [No Abstract]   [Full Text] [Related]  

  • 4. Pharmaceutical expenditure compared across countries.
    van Mosseveld C
    Can J Clin Pharmacol; 2005; 12(3):e269-75. PubMed ID: 16373959
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmaceutical policy in Italy: towards a structural change?
    Ghislandi S; Krulichova I; Garattini L
    Health Policy; 2005 Apr; 72(1):53-63. PubMed ID: 15760698
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The UK pharmaceutical market. An overview.
    Towse A
    Pharmacoeconomics; 1996; 10 Suppl 2():14-25. PubMed ID: 10163432
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pricing and reimbursement of pharmaceuticals in the Czech Republic and Sweden.
    Davidova J; Praznovcova L; Lundborg CS
    Pharm World Sci; 2008 Jan; 30(1):57-64. PubMed ID: 17588212
    [TBL] [Abstract][Full Text] [Related]  

  • 8. European prices of newly launched reimbursable pharmaceuticals--a pilot study.
    Martikainen J; Kivi I; Linnosmaa I
    Health Policy; 2005 Nov; 74(3):235-46. PubMed ID: 16226136
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The impact of repeated cost containment policies on pharmaceutical expenditure: experience in Spain.
    Moreno-Torres I; Puig-Junoy J; Raya JM
    Eur J Health Econ; 2011 Dec; 12(6):563-73. PubMed ID: 20809092
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The impact of pharmaceutical policy measures: an endogenous structural-break approach.
    Barros PP; Nunes LC
    Soc Sci Med; 2010 Aug; 71(3):440-450. PubMed ID: 20621744
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Historical overview of regulatory framework development on pricing and reimbursement of medicines in Bulgaria.
    Vassileva M; Kamusheva M; Manova M; Savova A; Tachkov K; Petrova G
    Expert Rev Pharmacoecon Outcomes Res; 2019 Dec; 19(6):733-742. PubMed ID: 30900482
    [No Abstract]   [Full Text] [Related]  

  • 12. Will lower drug prices jeopardize drug research? A policy fact sheet.
    Light DW; Lexchin J
    Am J Bioeth; 2004; 4(1):W1-4. PubMed ID: 15035915
    [No Abstract]   [Full Text] [Related]  

  • 13. Projecting future drug expenditures: 2011.
    Doloresco F; Fominaya C; Schumock GT; Vermeulen LC; Matusiak L; Hunkler RJ; Shah ND; Hoffman JM
    Am J Health Syst Pharm; 2011 May; 68(10):921-32. PubMed ID: 21546644
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prescription drug prices in Canada.
    Gross D
    Issue Brief (Public Policy Inst (Am Assoc Retired Pers)); 2003 Jun; (IB62):1-22. PubMed ID: 12807123
    [No Abstract]   [Full Text] [Related]  

  • 15. Lowering Part D drug costs without direct CMS negotiations.
    Sipkoff M
    Manag Care; 2009 Sep; 18(9):11-2. PubMed ID: 19886203
    [No Abstract]   [Full Text] [Related]  

  • 16. [Pharmaceutical reference pricing in Germany: definition of therapeutic groups, price setting through regression procedure and effects].
    Stargardt T; Schreyögg J; Busse R
    Gesundheitswesen; 2005 Jul; 67(7):468-77. PubMed ID: 16103970
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Seniors' prescription drug cost inflation and cost containment: evidence from British Columbia.
    Morgan SG; Agnew JD; Barer ML
    Health Policy; 2004 Jun; 68(3):299-307. PubMed ID: 15113641
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Spending on medicines in Israel in an international context.
    Sax P
    Isr Med Assoc J; 2005 May; 7(5):286-91. PubMed ID: 15909459
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Problematic Jumps in Drug Prices and What You Can Do.
    Shaughnessy AF
    Am Fam Physician; 2017 Jul; 96(1):16-18. PubMed ID: 28671371
    [No Abstract]   [Full Text] [Related]  

  • 20. Reference-based pricing schemes: effect on pharmaceutical expenditure, resource utilisation and health outcomes.
    Ioannides-Demos LL; Ibrahim JE; McNeil JJ
    Pharmacoeconomics; 2002; 20(9):577-91. PubMed ID: 12141886
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.